GLP-1 agonists may have turned obesity treatment upside down, becoming a viral phenomenon thanks to social media acclaim and celebrity endorsements along with their ability to support tangible weight loss results for many patients. But the skyrocketing demand for these therapies has a shadow side, leading to supply shortages, access inequities and bureaucratic hurdles that…